Nicholas Hoffman & Company LLC. Has $5.25 Million Position in Johnson & Johnson (NYSE:JNJ)

Nicholas Hoffman & Company LLC. reduced its stake in Johnson & Johnson (NYSE:JNJ) by 4.6% in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 32,381 shares of the company’s stock after selling 1,544 shares during the quarter. Nicholas Hoffman & Company LLC.’s holdings in Johnson & Johnson were worth $5,248,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Mirador Capital Partners LP lifted its stake in shares of Johnson & Johnson by 4.2% during the first quarter. Mirador Capital Partners LP now owns 20,508 shares of the company’s stock valued at $3,244,000 after acquiring an additional 833 shares during the period. Aviance Capital Partners LLC lifted its stake in Johnson & Johnson by 63.3% in the first quarter. Aviance Capital Partners LLC now owns 37,818 shares of the company’s stock valued at $5,982,000 after buying an additional 14,663 shares during the period. Skyline Advisors Inc. lifted its stake in Johnson & Johnson by 3.5% in the first quarter. Skyline Advisors Inc. now owns 2,478 shares of the company’s stock valued at $392,000 after buying an additional 83 shares during the period. Wolff Wiese Magana LLC lifted its stake in Johnson & Johnson by 8.0% in the first quarter. Wolff Wiese Magana LLC now owns 3,950 shares of the company’s stock valued at $625,000 after buying an additional 294 shares during the period. Finally, BKM Wealth Management LLC lifted its stake in Johnson & Johnson by 16.3% in the first quarter. BKM Wealth Management LLC now owns 14,473 shares of the company’s stock valued at $2,289,000 after buying an additional 2,025 shares during the period. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, VP Robert J. Decker sold 5,635 shares of Johnson & Johnson stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $165.06, for a total transaction of $930,113.10. Following the completion of the sale, the vice president now directly owns 18,973 shares of the company’s stock, valued at approximately $3,131,683.38. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.16% of the stock is currently owned by insiders.

Johnson & Johnson Stock Up 0.3 %

JNJ stock opened at $160.62 on Thursday. The company has a quick ratio of 0.85, a current ratio of 1.07 and a debt-to-equity ratio of 0.44. The business has a 50 day moving average price of $163.44 and a two-hundred day moving average price of $155.32. The company has a market cap of $386.56 billion, a price-to-earnings ratio of 10.01, a P/E/G ratio of 2.90 and a beta of 0.52. Johnson & Johnson has a twelve month low of $143.13 and a twelve month high of $168.85.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.21 by $0.21. Johnson & Johnson had a return on equity of 35.46% and a net margin of 19.14%. The company had revenue of $22.47 billion during the quarter, compared to analysts’ expectations of $22.17 billion. During the same period last year, the firm posted $2.66 earnings per share. The business’s revenue was up 5.2% on a year-over-year basis. Analysts anticipate that Johnson & Johnson will post 9.94 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Tuesday, November 26th will be issued a dividend of $1.24 per share. The ex-dividend date is Tuesday, November 26th. This represents a $4.96 annualized dividend and a yield of 3.09%. Johnson & Johnson’s payout ratio is currently 30.92%.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on JNJ shares. Royal Bank of Canada increased their target price on Johnson & Johnson from $178.00 to $181.00 and gave the company an “outperform” rating in a research note on Wednesday, October 16th. TD Securities lowered their price target on Johnson & Johnson from $195.00 to $185.00 in a report on Thursday, July 18th. Sanford C. Bernstein increased their price target on Johnson & Johnson from $161.00 to $171.00 in a report on Thursday, July 18th. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, September 14th. Finally, The Goldman Sachs Group lowered their price target on Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating for the company in a report on Friday, July 19th. Six research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $175.93.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.